Glenview Trust co Has $427,000 Stock Position in Agilent Technologies, Inc. $A

Glenview Trust co raised its stake in Agilent Technologies, Inc. (NYSE:A) by 64.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,646 shares of the medical research company’s stock after acquiring an additional 1,435 shares during the quarter. Glenview Trust co’s holdings in Agilent Technologies were worth $427,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Agilent Technologies by 13.5% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company’s stock worth $4,279,000 after acquiring an additional 4,362 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Agilent Technologies by 8.3% in the first quarter. Assenagon Asset Management S.A. now owns 30,827 shares of the medical research company’s stock worth $3,606,000 after acquiring an additional 2,371 shares during the last quarter. Alps Advisors Inc. raised its stake in shares of Agilent Technologies by 29.5% in the first quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company’s stock worth $1,563,000 after acquiring an additional 3,040 shares during the last quarter. D.A. Davidson & CO. raised its stake in shares of Agilent Technologies by 30.4% in the first quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company’s stock worth $1,108,000 after acquiring an additional 2,207 shares during the last quarter. Finally, LGT Capital Partners LTD. raised its stake in shares of Agilent Technologies by 7.6% in the first quarter. LGT Capital Partners LTD. now owns 768,252 shares of the medical research company’s stock worth $89,870,000 after acquiring an additional 54,302 shares during the last quarter.

Analyst Upgrades and Downgrades

A has been the subject of a number of research analyst reports. UBS Group dropped their target price on shares of Agilent Technologies from $150.00 to $130.00 and set a “neutral” rating for the company in a research note on Thursday, May 29th. JPMorgan Chase & Co. dropped their target price on shares of Agilent Technologies from $160.00 to $155.00 and set an “overweight” rating for the company in a research note on Thursday, May 29th. Evercore ISI dropped their target price on shares of Agilent Technologies from $130.00 to $128.00 and set an “in-line” rating for the company in a research note on Thursday, August 28th. Wall Street Zen cut shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research report on Friday, September 5th. Finally, TD Cowen lifted their price target on shares of Agilent Technologies to $150.00 and gave the stock a “buy” rating in a research report on Thursday, May 29th. Six research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $139.25.

Agilent Technologies Stock Up 2.2%

Shares of NYSE:A opened at $126.88 on Friday. Agilent Technologies, Inc. has a one year low of $96.43 and a one year high of $153.84. The company has a 50 day moving average of $119.72 and a 200-day moving average of $116.07. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71. The stock has a market cap of $35.97 billion, a price-to-earnings ratio of 29.78, a P/E/G ratio of 3.86 and a beta of 1.24.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, hitting the consensus estimate of $1.37. The company had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. Agilent Technologies’s revenue was up 10.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.32 EPS. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. On average, sell-side analysts forecast that Agilent Technologies, Inc. will post 5.58 earnings per share for the current year.

Insider Transactions at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 1,508 shares of the business’s stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total transaction of $177,099.52. Following the completion of the transaction, the chief executive officer owned 37,448 shares in the company, valued at approximately $4,397,893.12. The trade was a 3.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.